Factor X Inhibitors
Items 1 to 10 of 16 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $155.00 | 18 | |
Rivaroxaban functions as a potent Factor Xa inhibitor, showcasing remarkable specificity in its interactions with the enzyme. Its unique structural features allow for effective binding within the active site, disrupting the coagulation cascade. The compound's conformational flexibility enhances its affinity, while its hydrophobic regions facilitate interactions with lipid membranes. Additionally, Rivaroxaban's kinetic profile reveals a rapid onset of action, underscoring its dynamic role in modulating enzymatic activity. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $235.00 $622.00 | 2 | |
Apixaban acts as a selective inhibitor of Factor Xa, characterized by its unique binding dynamics that stabilize the enzyme-inhibitor complex. Its distinct molecular architecture promotes strong interactions with key residues in the active site, effectively blocking substrate access. The compound exhibits a favorable pharmacokinetic profile, with a balanced distribution and elimination, allowing for predictable behavior in biological systems. Its solubility properties further enhance its interaction potential within various environments. | ||||||
Sodium succinate dibasic | 150-90-3 | sc-251053 | 100 g | $39.00 | ||
Sodium succinate dibasic functions as a versatile Factor X, exhibiting unique molecular interactions that facilitate its role in biochemical pathways. Its structure allows for effective coordination with metal ions, influencing reaction kinetics and enhancing catalytic efficiency. The compound's amphipathic nature contributes to its solubility in diverse environments, promoting interactions with various biomolecules. This behavior underscores its significance in modulating enzymatic activities and metabolic processes. | ||||||
p-APMSF, Hydrochloride | 74938-88-8 | sc-204155 sc-204155A sc-204155B sc-204155C | 5 mg 10 mg 50 mg 100 mg | $85.00 $109.00 $299.00 $560.00 | 1 | |
p-APMSF, Hydrochloride acts as a distinctive Factor X, characterized by its ability to form strong hydrogen bonds and hydrophobic interactions with target molecules. This compound exhibits selective reactivity, enabling it to modulate specific enzymatic pathways through competitive inhibition. Its unique electronic properties facilitate rapid reaction kinetics, while its solubility profile allows for effective integration into various biochemical systems, enhancing its role in molecular interactions. | ||||||
1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone, Dihydrochloride | sc-220558 | 5 mg | $462.00 | |||
1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone, Dihydrochloride serves as a notable Factor X, distinguished by its capacity to engage in specific electrostatic interactions and conformational changes within target proteins. This compound demonstrates a unique affinity for active sites, promoting selective binding that influences downstream signaling pathways. Its structural features enable it to stabilize transient complexes, thereby affecting reaction dynamics and enhancing the specificity of molecular recognition events. | ||||||
Gabexate mesylate | 56974-61-9 | sc-215066 | 5 mg | $100.00 | ||
Gabexate mesylate acts as a Factor X, characterized by its ability to modulate proteolytic activity through selective inhibition of serine proteases. Its unique structure facilitates strong hydrogen bonding and hydrophobic interactions with target enzymes, altering their conformation and activity. This compound exhibits rapid kinetics in binding, allowing for effective competition with substrate molecules, ultimately influencing the cascade of coagulation processes at a molecular level. | ||||||
Edoxaban | 480449-70-5 | sc-483508 | 25 mg | $522.00 | ||
A direct factor Xa inhibitor used for DVT and PE, as well as to reduce the risk of stroke in atrial fibrillation. | ||||||
GGACK | 65113-67-9 | sc-201314 sc-201314A sc-201314B | 5 mg 25 mg 100 mg | $315.00 $1375.00 $5000.00 | ||
GGACK functions as a Factor X, distinguished by its capacity to interact with specific protein domains, leading to the modulation of coagulation pathways. Its unique molecular architecture promotes effective electrostatic interactions with target proteins, enhancing binding affinity. The compound exhibits a notable propensity for conformational changes in its targets, which can significantly impact enzymatic activity. Additionally, GGACK's reaction kinetics reveal a swift association and dissociation profile, influencing the dynamics of coagulation cascades. | ||||||
Betrixaban | 330942-05-7 | sc-503540 | 100 mg | $7500.00 | ||
A direct factor Xa inhibitor indicated for extended prophylaxis of venous thromboembolism (VTE) | ||||||
Nafamostat mesylate | 82956-11-4 | sc-201307 sc-201307A | 10 mg 50 mg | $80.00 $300.00 | 4 | |
Nafamostat mesylate acts as a Factor X through its ability to selectively inhibit serine proteases involved in the coagulation cascade. Its unique structure allows for precise interactions with the active sites of target enzymes, facilitating competitive inhibition. The compound demonstrates rapid kinetics, characterized by a fast onset of action and a short half-life, which can alter the balance of hemostatic processes. Its distinct binding dynamics contribute to the modulation of thrombin generation and fibrin formation. | ||||||